{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-138263","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.258341+00:00","generated_at":"2026-06-02T01:08:17.343351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M","bullets":["Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.","Cash, equivalents and marketable securities of $597.0M as of March 31, 2024.","Acquisition of AnHeart Therapeutics closed in April 2024, transforming Nuvation into late-stage global oncology company.","Appointed Colleen Sjogren as Chief Commercial Officer; first patient dosed in Phase 1/2 study of NUV-1511 DDC.","Updated taletrectinib Phase 2 TRUST-I data to be presented at ASCO 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-138263","json":"https://secwatch.observer/filing/0001193125-24-138263.json","markdown":"https://secwatch.observer/filing/0001193125-24-138263.md","text":"https://secwatch.observer/filing/0001193125-24-138263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/0001193125-24-138263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/d693344d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:08:17.343351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f95aaa2abb54902c2770c17d82965afd608f6f8","claim":"Nuvation Bio Inc. reported the first quarter ended March 31, 2024 results: net income $14.8 million, EPS $(0.07) per share.","evidence_excerpt":"For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/0001193125-24-138263-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$14.8 million"},{"label":"EPS","value":"$(0.07) per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}